Savolitinib
- Generic Name
- Savolitinib
- Drug Type
- Small Molecule
- Chemical Formula
- C17H15N9
- CAS Number
- 1313725-88-0
- Unique Ingredient Identifier
- 2A2DA6857R
- Background
Savolitinib has been used in trials studying the treatment and health services research of Tumor, Food Effect, Gastric Cancer, Health Subjects, and Colorectal Cancer, among others.
- Indication
用于含铂化疗后疾病进展或不耐受标准含铂化疗的、具有间质-上皮转化因子（MET）外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者。
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
- Conditions
- Papillary Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 148
- Registration Number
- NCT05043090
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-08-20
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Hutchison Medipharma Limited
- Target Recruit Count
- 250
- Registration Number
- NCT05015608
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Hutchison Medipharma Limited
- Target Recruit Count
- 320
- Registration Number
- NCT05009836
- Locations
- 🇨🇳
Guangdong General Hospital, Guangzhou, China
Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Hutchison Medipharma Limited
- Target Recruit Count
- 203
- Registration Number
- NCT04923945
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients
- Conditions
- Gastric CancerEsophagogastric Junction Disorder
- Interventions
- First Posted Date
- 2021-06-11
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- Hutchison Medipharma Limited
- Target Recruit Count
- 75
- Registration Number
- NCT04923932
- Locations
- 🇨🇳
Beijing Cancer Hopspital, Beijing, Beijing, China
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-10-28
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT04606771
- Locations
- 🇻🇳
Research Site, Ho Chi Minh city, Vietnam
A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body
- First Posted Date
- 2019-12-05
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT04187456
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With Famotidine
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT04179071
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT04121910
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT04118842
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.